FDA grants orphan drug designation for Marinus’ Ganaxolone IV to treat status epilepticus
A Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of ganaxolone IV is expected to initiate in the first half of 2016. Marinus Pharmaceuticals CEO Christopher
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.